Figures computed from official regulatory filings — .
Ownershipinsiders 13.22% · institutions 14.23%
In EUR · as of Oct 19, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for GENFIT only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Genfit S.A., together with its subsidiaries, engages in the research and development of medicines and diagnostic solutions in France and internationally. The company offers elafibranor for the treatment of primary biliary cholangitis; and NIS, a non-invasive diagnostic technology for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops elafibranor, which is in Phase 3 clinical trial for the treatment of primary sclerosing cholangitis; GNS561, which is in Phase 1b clinical trial for the treatment of cholangiocarcinoma; and G1090N/NTZ, which is in Phase 1 clinical trial for the treatment of acute-on-chronic liver failure continuum. In addition, the company is involved in the development of drugs in preclinical stage, including SRT-015, CLM-022, and EViv for the treatment of acute-on-chronic liver failure continuum; VS-02-HE for the treatment of hepatic encephalopathy; and VS-01-HAC (UCD/OA) for the treatment of hyperammonemic crises, urea cycle disorder, and organic acidemias. It has strategic partnerships with Ipsen for the development and commercialization of elafibranor; and Labcorp for the development and commercialization of NASHnext, a blood-based molecular diagnostic test, as well as TS-01, a diagnostic tool for blood ammonia levels. The company was incorporated in 1999 and is headquartered in Loos, France.
Market information source · Oct 19, 2026
Open-market timeline · full history
6 buys1 sell— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| PASCAL CAISEY | Sell | $314.2K | AMF |
| PASCAL CAISEY | ExerciseD (derivative) | $105.3K | AMF |
| jean francois tine | Buy | $21.4K | conv 45Cluster | AMF |
| Pascal Prigent | Buy | $40.2K | conv 59First in 12mo | AMF |
| Jean-François MOUNEY | Buy | $40.2K | conv 65ClusterFirst in 12mo | AMF |
| jean francois tine | Buy | $20.5K | conv 49First in 12mo | AMF |
| Pascal Prigent | Exercise | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | AMF |
| Jean-François MOUNEY | Exercise | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | AMF |
| Pascal Prigent | Buy | $38.6K | conv 44First in 12mo | AMF |
| Jean-François MOUNEY | Buy | $38K | conv 36First in 12mo | AMF |